{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:13Z","timestamp":1792784593696,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"am","delay-in-days":396,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Johnson & Johnson","award":["OPP1084240"],"award-info":[{"award-number":["OPP1084240"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.10.091","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T08:24:58Z","timestamp":1446625498000},"page":"6611-6616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Production of high titer attenuated poliovirus strains on the serum-free PER.C6\u00ae cell culture platform for the generation of safe and affordable next generation IPV"],"prefix":"10.1016","volume":"33","author":[{"given":"Barbara P.","family":"Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel de los Rios","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred","family":"Marissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Minor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckard","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H.H.V.","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Macadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeronimo","family":"Cello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Edo-Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.10.091_bib0205","unstructured":"GPEI. History of Polio: http:\/\/www.polioeradication.org\/Polioandprevention\/Historyofpolio.aspx. 2015."},{"issue":"11","key":"10.1016\/j.vaccine.2015.10.091_bib0210","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jama.1957.62980110008008","article-title":"Properties and behavior of orally administered attenuated poliovirus vaccine","volume":"164","author":"Sabin","year":"1957","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0215","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","article-title":"Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines","volume":"44","author":"Salk","year":"1954","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0220","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/erv.12.28","article-title":"Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis","volume":"11","author":"Pliaka","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0225","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0230","series-title":"Polio Eradication & Endgame Strategic Plan 2013\u20132018","author":"WHO","year":"2013"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0235","first-page":"197","article-title":"Anomalous observations on IPV and OPV vaccination","volume":"105","author":"John","year":"2001","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0240","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(88)91711-4","article-title":"Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine","volume":"1","author":"Robertson","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0245","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","volume":"28","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0250","series-title":"An economic analysis of strategies to reduce the cost of routine IPV immunization","article-title":"Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries","author":"Zehrung","year":"2010"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0255","article-title":"Recommendations for the production and control of poliomyelitis vaccine (inactivated)","author":"WHO","year":"2002"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0260","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0265","article-title":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan","author":"Shimizu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0270","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.vaccine.2013.12.025","article-title":"Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine","volume":"32","author":"Sun","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0275","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0280","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","author":"Fallaux","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0285","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.vaccine.2012.10.070","article-title":"PER.C6((R)) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine","volume":"31","author":"Sanders","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0290","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1073\/pnas.83.8.2330","article-title":"Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase","volume":"83","author":"van der Werf","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0295","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1099\/vir.0.000197","article-title":"Brunenders: a partially attenuated historic poliovirus Type I vaccine strain","volume":"96","author":"Sanders","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0300","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1128\/JVI.00370-06","article-title":"Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication","volume":"80","author":"Macadam","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0305","unstructured":"Inactivated Poliovaccine International Patent Number: WO 2012\/090000 A1. United Kingdom 2012."},{"key":"10.1016\/j.vaccine.2015.10.091_bib0310","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1099\/vir.0.036988-0","article-title":"The polio-eradication programme and issues of the end game","volume":"93","author":"Minor","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0315","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1128\/JVI.77.9.5152-5166.2003","article-title":"Functional dissection of a poliovirus cis-acting replication element [PV-cre(2C)]: analysis of single- and dual-cre viral genomes and proteins that bind specifically to PV-cre RNA","volume":"77","author":"Yin","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0320","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-06-3713","article-title":"Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model","volume":"67","author":"Toyoda","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0325","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1126\/science.1155761","article-title":"Virus attenuation by genome-scale changes in codon pair bias","volume":"320","author":"Coleman","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0330","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/es60130a004","article-title":"Trimmed Spearman\u2013Karber method for estimating median lethal concentration in toxicity bioassays","volume":"11","author":"Hamilton","year":"1977","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0335","doi-asserted-by":"crossref","first-page":"e83374","DOI":"10.1371\/journal.pone.0083374","article-title":"Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals","volume":"8","author":"Thomassen","year":"2013","journal-title":"PloS ONE"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/vim.1990.3.243","article-title":"Production of poliovirus vaccines: past, present, and future","volume":"3","author":"Duchene","year":"1990","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0345","first-page":"55","article-title":"The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine","volume":"47","author":"Montagnon","year":"1981","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0350","first-page":"65","article-title":"Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines","volume":"42","author":"van Wezel","year":"1979","journal-title":"Dev Biol Stand"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2015.10.091_bib0355","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/clinids\/6.Supplement_2.S335","article-title":"Inactivated poliovirus vaccine: current production methods and new developments","volume":"6","author":"van Wezel","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0360","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0365","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","volume":"34","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0370","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bit.24798","article-title":"Scale-down of the inactivated polio vaccine production process","volume":"110","author":"Thomassen","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0375","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nrmicro1769","article-title":"Vaccination against polio should not be stopped","volume":"5","author":"Chumakov","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0380","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.vaccine.2015.02.013","article-title":"Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses","volume":"33","author":"Thompson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0385","series-title":"The accidental release of 45 litres of concentrated live polio virus solution into the environment\u2014Belgium monitoring current threats: ECDC communicable disease threats report (CDTR), week 37\/2014","author":"ECDC","year":"2014"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0390","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jit155","article-title":"Phase II and III clinical studies of Diphtheria\u2013Tetanus\u2013Acellular Pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV)","volume":"208","author":"Okada","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.10.091_bib0395","doi-asserted-by":"crossref","first-page":"358462","DOI":"10.1155\/2015\/358462","article-title":"Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1","volume":"2015","author":"Oosterhoff","year":"2015","journal-title":"BioMed Res Int"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2015.10.091_bib0400","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/infdis\/jiu128","article-title":"Affordable inactivated poliovirus vaccine: strategies and progress","volume":"210","author":"Okayasu","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15015479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:21:37Z","timestamp":1759400497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15015479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":40,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0264410X15015479"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.091","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of high titer attenuated poliovirus strains on the serum-free PER.C6\u00ae cell culture platform for the generation of safe and affordable next generation IPV","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}